Eden Ben

Chief Executive Officer at AMORPHICAL

Eden Ben serves as the Vice President of the Animal Health Department and Business Development at Amorphical, specializing in sales management, new market development, clinical trials, and drug development aligned with market needs. Experience includes previous roles as Director in the same departments at Amorphical, and as a partner and manager at Antelope Ranch, overseeing daily operations and field management. Prior business development management experience spans agrotech, tourism, and pharmaceuticals, along with an apprenticeship in business development at Amorphical. Earlier career highlights include a role in security for cargo ships and service as a combat soldier in the Israel Defense Forces. Eden Ben holds a B.Sc in Biomedical/Medical Engineering from Afeka Tel Aviv Academic College of Engineering.

Location

Tel Aviv, Israel

Links

Previous companies


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices


AMORPHICAL

Pioneer Israeli Biotechnology Company Established in 2004 developing novel solutions for number of major diseases. Amorphical has successfully developed a unique and stable form of Amorphous Calcium Carbonate (ACC), in nano-particle form (20-80 nm) employing proprietary process based on biomimicry-searching methods utilized by certain mammals. The unique features of ACC have demonstrated novel modes of actions that enable disease treatment in a number of conditions, as well as performance improvement of cells and organs. ACC has a much higher solubility than crystalline calcium carbonate (CCC) at mildly acidic conditions and neutral pH (100 times higher), compared to all similar calcium products in the market including Pfizer’s and GNC’s. ACC consists of nanometric primary particles in the range of 20 to 80 nanometers that are slightly agglomerated. ACC has a remarkable higher (double) calcium absorption, compared to other calcium supplement substances. ACC has remarkable higher calcium bioavailability and higher bioactivity, which is attributed to ACC’s capability to deliver the carbonate domains as a solid nanometric buffer.


Headquarters

Nes Ziona, Israel

Employees

51-200

Links